Neos Therapeutics (NEOS) Trading Down 7.7%

Share on StockTwits

Neos Therapeutics Inc (NASDAQ:NEOS) shares dropped 7.7% on Monday . The company traded as low as $2.01 and last traded at $2.05. Approximately 509,073 shares were traded during trading, an increase of 37% from the average daily volume of 371,612 shares. The stock had previously closed at $2.22.

NEOS has been the topic of a number of recent analyst reports. Cantor Fitzgerald set a $20.00 price objective on Neos Therapeutics and gave the stock a “buy” rating in a report on Wednesday, December 26th. Zacks Investment Research raised Neos Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a report on Wednesday, January 16th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $9.69.

The company has a quick ratio of 1.37, a current ratio of 1.55 and a debt-to-equity ratio of 5.51. The stock has a market cap of $105.39 million, a PE ratio of -1.31 and a beta of 0.99.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. The company had revenue of $15.39 million during the quarter, compared to analysts’ expectations of $18.90 million. Analysts forecast that Neos Therapeutics Inc will post -0.66 EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. Nantahala Capital Management LLC purchased a new position in Neos Therapeutics during the fourth quarter worth about $7,400,000. Stonepine Capital Management LLC lifted its position in Neos Therapeutics by 1,747.2% during the fourth quarter. Stonepine Capital Management LLC now owns 4,210,153 shares of the company’s stock worth $6,947,000 after buying an additional 3,982,234 shares during the period. Broadfin Capital LLC purchased a new position in Neos Therapeutics during the fourth quarter worth about $4,321,000. Sphera Funds Management LTD. lifted its position in Neos Therapeutics by 164.7% during the fourth quarter. Sphera Funds Management LTD. now owns 2,201,697 shares of the company’s stock worth $3,633,000 after buying an additional 1,370,000 shares during the period. Finally, BlackRock Inc. lifted its position in Neos Therapeutics by 28.8% during the fourth quarter. BlackRock Inc. now owns 2,733,411 shares of the company’s stock worth $4,510,000 after buying an additional 610,660 shares during the period. Institutional investors and hedge funds own 50.83% of the company’s stock.

WARNING: This report was first reported by Fairfield Current and is the property of of Fairfield Current. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.fairfieldcurrent.com/news/2019/04/17/neos-therapeutics-neos-trading-down-7-7.html.

Neos Therapeutics Company Profile (NASDAQ:NEOS)

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Recommended Story: Do back-end load funds outperform no-load funds?

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply